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Temporal lobe epilepsy (TLE) is a prevalent neurological disorder with many patients experiencing poor seizure control
with existing anti-epileptic drugs. Thus, novel insights into the
mechanisms of epileptogenesis and identification of new drug
targets can be transformative. Changes in ion channel function
have been shown to play a role in generating the aberrant neuronal activity observed in TLE. Previous work demonstrates that
hyperpolarization-activated cyclic nucleotide-gated (HCN)
channels regulate neuronal excitability and are mislocalized
within CA1 pyramidal cells in a rodent model of TLE. The subcellular distribution of HCN channels is regulated by an auxiliary subunit, tetratricopeptide repeat– containing Rab8b-interacting protein (TRIP8b), and disruption of this interaction
correlates with channel mislocalization. However, the molecular mechanisms responsible for HCN channel dysregulation in
TLE are unclear. Here we investigated whether changes in
TRIP8b phosphorylation are sufficient to alter HCN channel
function. We identified a phosphorylation site at residue Ser237
of TRIP8b that enhances binding to HCN channels and influences channel gating by altering the affinity of TRIP8b for the
HCN cytoplasmic domain. Using a phosphospecific antibody,
we demonstrate that TRIP8b phosphorylated at Ser237 is enriched in CA1 distal dendrites and that phosphorylation is
reduced in the kainic acid model of TLE. Overall, our findings
indicate that the TRIP8b–HCN interaction can be modulated
by changes in phosphorylation and suggest that loss of TRIP8b
phosphorylation may affect HCN channel properties during
epileptogenesis. These results highlight the potential of drugs
targetingposttranslationalmodificationstorestoreTRIP8bphosphorylation to reduce excitability in TLE.
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An estimated 3.4 million patients suffer from epilepsy in the
United States, and temporal lobe epilepsy (TLE)2 represents
one of the most common drug-resistant forms of the disorder
(1–3). Although many patients with TLE respond to anti-epileptic drugs, one-third of individuals experience seizures that
are refractory to medical treatment (4). Changes in ion channel
function that contribute to the epileptic state are observed in
individuals suffering from inherited epilepsies and in rodent
models of TLE (5–10). Therefore, understanding ion channelopathy in the context of epilepsy may lead to new targets for
drugs to treat this disorder.
Hyperpolarization-activated cyclic nucleotide-gatedtk; (HCN1–
HCN4) channels are nonspecific cation channels that mediate
the Ih current and are highly expressed in the hippocampus
(11). HCN1 and HCN2 channels are enriched in the distal dendrites of CA1 pyramidal cells, where they limit neuronal excitability and regulate temporal summation and dendritic integration (12–15). The intracellular region of the HCN channel
consists of a cyclic nucleotide-binding domain (CNBD) that
binds cAMP and a C-terminal tail consisting of the amino acids
serine, asparagine, and leucine (SNL), which are also involved
in protein binding. Binding of cAMP to the CNBD speeds channel activation kinetics and depolarizes the activation voltage
(16 –19).
Within CA1 pyramidal neurons, the auxiliary subunit tetratricopeptide repeat– containing Rab8b-interacting protein
(TRIP8b) regulates the subcellular location and function of
HCN channels (20 –25). TRIP8b is a cytosolic protein that
directly binds to HCN channels at two distinct locations to
hyperpolarize channel gating and facilitate dendritic trafficking
(21, 26). Within the HCN channel intracellular C-terminus,
TRIP8b binds to the CNBD, where it acts as a competitive

2

The abbreviations used are: TLE, temporal lobe epilepsy; CNBD, cyclic nucleotide binding domain; HCN channel, hyperpolarization-activated cyclic
nucleotide-gated channel; TPR, tetratricopeptide repeat; TKO, TRIP8b
knockout; CaMKII, calcium/calmodulin-dependent protein kinase II; aa,
amino acids; CIP, calf intestinal phosphatase; SE, status epilepticus; Sal,
saline; BME, ␤-mercaptoethanol; KA, kainic acid; RRID, research resource
identifier.
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Results
Identification of phosphorylation site Ser237 on TRIP8b
A previous global phosphoproteome analysis identified several possible phosphorylation sites on TRIP8b, including on
residue Ser237 (53). We immunopurified TRIP8b from hippocampal lysates prepared from both a control rat and a rat
subjected to kainic acid (KA)–induced seizures. We then subjected the immunopurified and gel-purified TRIP8b protein
to LC-MS/MS. As shown in Fig. 1, we obtained extensive
sequence coverage of the rat TRIP8b protein isoform 1a-4 (UniProt Q925N3) from both samples (473/602 aa or 79% from
control and 294/602 or 49% from KA-treated). Fig. 1C shows a
representative MS/MS spectrum of the peptide NHSLEEEFER
(aa 235–244) that demonstrates unambiguous identification of
in vivo phosphorylation of TRIP8b at Ser237. Phosphorylation at
Ser237 was identified on TRIP8b purified from both control and
KA-treated rats. The normalized spectral counts for the phosphopeptide containing Ser237 were present at a lower level in
the KA-induced seizure sample than in the control sample (data
not shown), suggesting that phosphorylation at this site may be
affected by acute seizures.
Ser237 is located within a conserved “nano” domain of
TRIP8b (residues 235–275) that is highly conserved across vertebrate species (Fig. 2, A and B). This previously identified nano
domain directly binds to the CNBD of HCN channels and competes with cAMP binding (54). Additionally, removing a segment of TRIP8b that contains the nano domain prevented distal dendritic enrichment of HCN1 in vivo (22). Given that the
Ser237 site is included within this functional domain, we
hypothesized that Ser237 phosphorylation could play a key role
in regulating the TRIP8b–HCN interaction.
Generation and validation of the phosphospecific antibody
pSer237
An antibody targeted against pSer237 (the phosphorylated
TRIP8b residue Ser237) was generated using a 15-amino acid
sequence that included the phosphorylated serine in the
TRIP8b nano domain as the antigen (see “Experimental procedures”). The specificity of this antibody for the phosphorylated
serine was confirmed in Western blots with native and dephosphorylated TRIP8b. Hippocampi from WT mice were incubated with or without the calf intestinal phosphatase (CIP), and
the lysates were probed with antibodies targeting total-TRIP8b,
pSer237, and ␣-tubulin (Fig. 2C). Although total TRIP8b was
expressed in both samples, the signal from the pSer237 antibody
was largely reduced with addition of the phosphatase. Additionally, the pSer237 antibody did not detect any protein in hippocampi from TKO mice (Fig. 2C). Thus, the pSer237 antibody
is specific for the phosphorylated serine residue on TRIP8b.
Based on the TRIP8b sequence and known protein kinase
motifs, we predicted that CaMKII␣ and PKA would phosphorylate TRIP8b(Ser237) (55). We performed in vitro protein kinase
assays to investigate this possibility by incubating purified
TRIP8b protein with CaMKII␣ or PKA, with or without ATP, at
30 °C for 30 min. The reaction mixtures were immunoblotted
using antibodies against pSer237 and TRIP8b (Fig. 2D). Treatment of TRIP8b with CaMKII␣ or PKA in the presence of ATP
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antagonist to inhibit cAMP binding (16, 21, 27–29). The second
TRIP8b–HCN interaction occurs between the TRIP8b tetratricopeptide repeat (TPR) domains and the HCN channel C-terminal tail (26, 30). Disrupting the CNBD binding interaction
prevents TRIP8b-mediated hyperpolarization of channel gating (21, 26). Both binding sites are necessary for proper dendritic trafficking in vivo, and disruption of either the CNBD or
C-terminal tail interaction precludes dendritic enrichment of
HCN channels by TRIP8b (22). TRIP8b contains an alternatively spliced N terminus, and the isoforms are named according to included exons. Isoform 1a-4 enhances channel surface
expression, dendritic trafficking, and current density (20, 22).
In TRIP8b knockout (TKO) mice, there is significant loss of
dendritic HCN channels with a concomitant reduction in Ih,
highlighting the importance of TRIP8b for channel function
(31).
Genetic screens of patients with epilepsy have identified several mutations in HCN channels and their auxiliary subunits
(32–38). In rodents, reduced HCN1 expression results in
enhanced neuronal excitability as well as increased seizure susceptibility and seizure-related death (15, 39–41). In animal
models of TLE, there is loss of Ih, reduced surface expression,
and hyperpolarization of channel activation in chronic epilepsy
(42–46). Prior work demonstrated mislocalization of the channels throughout CA1 pyramidal cell dendrites that correlated
with disruption of the TRIP8b–HCN interaction (47). These
results raise the possibility that loss of TRIP8b function is
responsible for HCN channel dysregulation in TLE. However, it
has been unclear what molecular mechanism might be responsible for regulating the TRIP8b–HCN interaction in vivo. We
hypothesized that posttranslational modifications of TRIP8b
would limit binding to HCN channels and affect channel
function.
HCN channel trafficking and gating can be modulated by
changes in kinase or phosphatase activity, including calcium/
calmodulin-dependent protein kinase II (CaMKII), p38 mitogen-activated kinase and PKC activity (48 –50). During epileptogenesis, several alterations in kinase and phosphatase activity
have been observed (43, 51, 52). Thus, we sought to determine
whether changes in TRIP8b phosphorylation would affect HCN
channel function and whether TRIP8b phosphorylation is dysregulated in TLE.
Through phosphoproteomics analysis, we and others identified a phosphorylation site on TRIP8b at residue Ser237 that is
located within the TRIP8b domain critical for CNBD binding
(53). We generated a phosphospecific antibody targeting residue Ser237 on TRIP8b and determined that TRIP8b is phosphorylated at Ser237 in areas of dendritic HCN channel enrichment.
The phosphorylation of this site enhances TRIP8b binding to
the HCN channel CNBD and is necessary for TRIP8b-mediated
hyperpolarization of channel gating. Additionally, we determined that both phosphorylation of this residue and CaMKII␣
activity are significantly reduced during epileptogenesis in the
kainic acid model of TLE. This work demonstrates that restoring TRIP8b phosphorylation may enhance HCN channel function in the distal dendrites of the CA1 and reduce neuronal
excitability in epilepsy.

TRIP8b phosphorylation modulates HCN channel function

enhanced the pSer237 signal compared with the nonphosphorylated protein without ATP. These data demonstrate that both
CaMKII␣ and PKA can phosphorylate the Ser237 residue of
TRIP8b in vitro.
Localization of phosphorylated TRIP8b in the brain
To determine the subcellular distribution of the phosphorylated TRIP8b protein, we performed immunohistochemistry.
In the mouse hippocampus, we found that phosphorylated
TRIP8b is enriched in the CA1 in a pattern similar to HCN1 and
TRIP8b. The data show that HCN1, total TRIP8b, and phosphorylated TRIP8b are expressed in distal dendrites of CA1
pyramidal cells in the stratum lacunosum molecular layer (Fig.
3, A and B, asterisks) (HCN1 (WT: 1, TKO: 0.52 ⫾ 0.03,
Student’s t test, p ⬍ 0.001, n ⫽ 5), TRIP8b (WT: 1, TKO: 0.27 ⫾
0.02, p ⬍ 0.001, n ⫽ 5), pSer237 (WT: 1, TKO: 0.56 ⫾ 0.1, p ⫽
0.01, n ⫽ 5), mean ⫾ S.E.). TRIP8b isoform 1a-4, which
enhances HCN channel dendritic trafficking in the hippocampus, has also been shown to be enriched in this location through

use of an antibody targeting TRIP8b exon 4 (24) (Fig. 3, A and B)
(exon 4 (WT: 1, TKO: 0.5 ⫾ 0.1, p ⬍ 0.001, n ⫽ 6). Therefore,
consistent with our LC-MS/MS results, we hypothesized that
isoform 1a-4 in particular is phosphorylated at Ser237. We used
an ␣-exon 4 antibody to immunoprecipitate TRIP8b isoforms
containing exon 4 (the majority of which is isoform 1a-4 (23))
from mouse hippocampal lysate. The total TRIP8b antibody
detected several TRIP8b isoforms that were present in the hippocampal input sample (Fig. 3C). However, the pSer237 antibody primarily detected one band that was enriched following
immunoprecipitation with the ␣-exon 4 antibody. The pSer237
band corresponds to the isoform 1a-4 band and confirms that,
indeed, isoform 1a-4 is significantly phosphorylated in the hippocampus (Fig. 3C).
Because HCN1 is also trafficked to the distal dendrites of the
neocortex in a TRIP8b-dependent manner (31), we examined
the retrosplenial and parietal association cortices (Fig. 3, D and
E). We observed a similar pattern of pSer237 staining with
greater expression in the distal dendrites in layer I (HCN1 (WT:
J. Biol. Chem. (2019) 294(43) 15743–15758
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Figure 1. Identification of in vivo TRIP8b phosphorylation at Ser237. A and B, TRIP8b was immunopurified from hippocampal lysates prepared from saline
(control) or KA-seized (Racine scale level 5) rats. TRIP8b immunoprecipitation products were analyzed by MS/MS. Spectral coverage of TRIP8b immunopurified
from hippocampal lysates from saline-treated (A) and KA-treated (B) rats is highlighted in yellow. pSer237 is highlighted in green within the recovered tryptic
peptide fragment, as indicated by the double underline. C, deconvolution of a representative pSer237-containing peptide MS/MS spectrum of the phosphopeptide NHpSLEEEFER derived from TRIP8b immunopurified from a hippocampal lysate prepared from a saline-treated rat. The fragmentation pattern of
the peptide is shown, highlighting that the y8 peptide includes the phosphorylated Ser237 residue yielding a 98 m/z shift on the x axis. An m/z shift of ⫹2 for
Ser237 was detected with a confidence score of 10⫺7.6, indicating a low probability of mistaken identification of Ser237 phosphorylation. D, summary of the
overall spectral coverage of TRIP8b from saline-treated and KA-treated rats, including the overall sequence coverage as shown in A and B.

TRIP8b phosphorylation modulates HCN channel function

1, TKO: 0.5 ⫾ 0.1, Student’s t test, p ⫽ 0.01, n ⫽ 4), TRIP8b
(WT: 1, TKO: 0.35 ⫾ 0.06, p ⫽ 0.002, n ⫽ 4), pSer237 (WT: 1,
TKO: 0.7 ⫾ 0.1, p ⫽ 0.04, n ⫽ 5)). These results indicate that
both the CA1 and neocortex express HCN1, TRIP8b, and
pSer237 enrichment in distal dendrites.
We then examined other areas with TRIP8b expression to
determine whether the protein is phosphorylated at Ser237
throughout the brain. TRIP8b is expressed in oligodendrocytes
of hippocampal area CA3 (24) and the granular layer of the
cerebellum. TRIP8b Ser237 was not phosphorylated to a detectable degree in either region (Fig. 4, A and B). We noted that
nonphosphorylated TRIP8b specifically colocalizes with HCN2
in cerebellar oligodendrocytes but not with HCN1 in the Purkinje cell layer (Fig. S1). The data suggest that TRIP8b phosphorylated at Ser237 is neuron-specific in brain regions that
exhibit distal dendritic enrichment of HCN channels.
To confirm the brain region–specific nature of phosphorylated TRIP8b, we investigated TRIP8b and pSer237 levels in several brain regions using immunoblotting (Fig. 4, C and D).
These data show that phosphorylated TRIP8b is enriched in the
CA1 region (relative pSer237 level to total TRIP8b, 1.0) compared with the levels found in the dentate gyrus (0.2 ⫾ 0.1),
thalamus (0.3 ⫾ 0.1), neocortex (0.5 ⫾ 0.1), and cerebellum
(0.05 ⫾ 0.04) (p ⬍ 0.05, n ⫽ 3). Taken together, these results
demonstrate that TRIP8b isoform 1a-4 is phosphorylated at
Ser237 and highly enriched in the distal dendrites of CA1 pyramidal cells.
Phosphorylated TRIP8b at Ser237 enhances binding to HCN
channels
We reasoned that phosphorylation of Ser237 could regulate
the strength of the TRIP8b–HCN interaction, given that the

15746 J. Biol. Chem. (2019) 294(43) 15743–15758

residue is located within the nano domain of TRIP8b responsible for CNBD binding. We investigated this possibility using
coimmunoprecipitation. To isolate the effect of pSer237 specifically on CNBD binding, TRIP8b constructs with an ablated
C-terminal tail TRIP8b–HCN interaction were used. These constructs contain a mutation of a key residue in the third TPR
domain (N382A, previously referred to as TPR3-N13A) which
disrupts the downstream interaction with the HCN channel
C-terminal tail (21). TRIP8b constructs containing the N382A
mutation alone, a phosphoablative mutation (S237A,N382A), a
kinase consensus sequence mutation (R234A,N382A), or a negative control that disrupts both interaction sites (⌬58,N382A)
were analyzed (21) (Fig. 5A). Because the arginine located at
position 234 on TRIP8b is a critical residue in the consensus
motifs for both CaMKII␣ and PKA, the construct containing
the R234A mutation is also predicted to prevent phosphorylation (phosphoablative) (56, 57). WT TRIP8b was basally phosphorylated in HEK293T cells, whereas both phosphoablative
constructs show reduced signal from the ␣-pSer237 antibody
(Fig. 5B). These constructs were transfected into HEK293T
cells along with HCN1, HCN1 protein was immunoprecipitated from the lysates, and the level of TRIP8b bound to the
channel was quantified (Fig. 5, C and D). Compared with
TRIP8b(N382A), both phosphoablative constructs demonstrated reduced binding to HCN1 (relative enrichment of
TRIP8b(N382A), 100; TRIP8b(S237A,N382A), 78.2 ⫾ 7.0;
TRIP8b(R234A,N382A), 76.1 ⫾ 5.0; TRIP8b(⌬58,N382A),
2.1 ⫾ 1.0; p ⬍ 0.05, n ⫽ 4).
To confirm these results, we performed an additional in vitro
fluorescence polarization binding assay to analyze the interaction between TRIP8b and the CNBD of HCN channels (58).
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Figure 2. Location of Ser237 on TRIP8b and phosphospecific antibody validation. A, schematic of one subunit of an HCN channel and TRIP8b. The
intracellular CNBD of the HCN subunit and the C-terminal residues SNL are labeled. The unbound cAMP binding site is depicted on the CNBD. On TRIP8b, the
N-terminal variable domain, the nano domain (yellow shape), and the C-terminal TPR domains are indicated. Serine 237 is indicated (purple star) within the nano
domain of TRIP8b that interacts with the HCN CNBD. B, Ser237 (red text) is conserved in select vertebrates: Homo sapiens (human), Pan troglodytes (chimpanzee),
Macaca mulatta (rhesus monkey), Mus musculus (mouse), Rattus norvegicus (rat), Sus scrofa (pig), and Ovis aries (sheep). TRIP8b residue numbers are based on
isoform 1a-4 (UniProt Q925N3) as a reference. C, WT and TKO mouse hippocampal lysates incubated with or without CIP for 2 h at 37 °C, n ⫽ 4. Samples were
immunoblotted with antibodies against TRIP8b, pSer237, and ␣-tubulin. D, purified TRIP8b(219 – 602) protein incubated with CaMKII␣ or PKA with or without ATP
at 30 °C for 30 min; n ⫽ 3. Molecular mass markers are shown in kilodaltons.

TRIP8b phosphorylation modulates HCN channel function

This assay utilizes the change in polarization of a small, fluorescently tagged ligand (cAMP) whose polarization increases
after binding a much larger protein (CNBD) (59). cAMP displacement serves as a readout of the affinity of TRIP8b binding
because cAMP and TRIP8b compete for CNBD binding. We
utilized fixed concentrations of FITC-tagged cAMP (8f-cAMP, 10 nM) and the CNBD of HCN1 (CNBD387–591, 0.625
M) and titrated increasing concentrations of a TRIP8b fragment conserved across all isoforms that includes the full nano
domain through the C terminus of the protein (TRIP8b219–602).
Prior to titration, TRIP8b219 – 602 was incubated with CaMKII␣,
with or without ATP, at 30 °C for 30 min. Titrating increasing
concentrations of phosphorylated TRIP8b increased the affinity of TRIP8b for the HCN1 CNBD (IC50, 6.3 ⫾ 0.6 M) compared with nonphosphorylated TRIP8b (8.2 ⫾ 0.8 M) (p ⫽
0.001, n ⫽ 6; Fig. 5, E and F). There are no additional CaMKII␣

motifs near the CNBD-binding region of TRIP8b. Thus,
TRIP8b phosphorylated at Ser237 binds to the HCN1 CNBD to
a greater degree than nonphosphorylated TRIP8b.
Phosphoablative TRIP8b constructs prevent hyperpolarization
of HCN channel gating
The change in affinity for HCN1 resulting from TRIP8b
Ser237 phosphorylation could alter HCN channel gating or current density. To test this idea, we carried out patch clamp
recordings from HCN channels. TRIP8b hyperpolarizes channel activation and enhances the current density of both HCN1
and HCN2 channels; hence, we used HEK293 cells that stably
express HCN2 and exhibit robust currents. HEK293 cells (in
which TRIP8b Ser237 is phosphorylated under basal conditions)
stably expressing HCN2 were transfected with GFP and either
TRIP8b(WT), TRIP8b(S237A), TRIP8b(R234A), or a control
J. Biol. Chem. (2019) 294(43) 15743–15758
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Figure 3. Immunohistochemical localization of pSer237 in the CA1 and neocortical distal dendrites. A, the CA1 region of WT and TKO mice probed with
antibodies against HCN1, TRIP8b, pSer237, and TRIP8b exon 4. B, the distal dendritic region was quantified in each stain: HCN1 (WT: 1, TKO: 0.52 ⫾ 0.03,
Student’s t test, p ⬍ 0.001, n ⫽ 5), TRIP8b (WT: 1, TKO: 0.27 ⫾ 0.02, p ⬍ 0.001, n ⫽ 5), pSer237 (WT: 1, TKO: 0.56 ⫾ 0.1, p ⫽ 0.01, n ⫽ 5), and exon 4 (WT: 1, TKO:
0.5 ⫾ 0.1, p ⬍ 0.001, n ⫽ 6). C, mouse hippocampal extracts before (input) and after (eluate) immunoprecipitation (IP) with an ␣-TRIP8b exon 4 antibody. Lysates
were immunoblotted with antibodies against TRIP8b and pSer237 (n ⫽ 3). D, neocortex region of WT and TKO mice probed with antibodies against HCN1,
TRIP8b, and pSer237. E, the distal dendritic region was quantified in each stain: HCN1 (WT: 1, TKO: 0.5 ⫾ 0.1, Student’s t test, p ⫽ 0.01, n ⫽ 4), TRIP8b (WT: 1, TKO:
0.35 ⫾ 0.06, p ⫽ 0.002, n ⫽ 4), and pSer237 (WT: 1, TKO: 0.7 ⫾ 0.1, p ⫽ 0.04, n ⫽ 5). Scale bars ⫽ 100 m; asterisks, distal dendritic region; SO, stratum oriens; SP,
stratum pyramidale; SR, stratum radiatum; SLM, stratum lacunosum moleculare. Molecular mass markers are shown in kilodaltons. All error bars represent
mean ⫾ S.E.

TRIP8b phosphorylation modulates HCN channel function

vector. As shown previously, expression of HCN2 with TRIP8b
hyperpolarized the voltage of half activation (V50; HCN2 ⫹ vector: ⫺90.1 ⫾ 1.6 mV, HCN2 ⫹ TRIP8b(WT): ⫺95.3 ⫾ 1.6 mV;
p ⬍ 0.05; n ⫽ 15, 13, respectively) (Fig. 6B). However, both
phosphoablative constructs prevented TRIP8b-mediated
hyperpolarization of channel gating (HCN2 ⫹ TRIP8b(S237A),
⫺88.3 ⫾ 2.2 mV; HCN2 ⫹ TRIP8b(R234A), ⫺83.9 ⫾ 2.3 mV;
p ⬍ 0.05; n ⫽ 14, 15, respectively). Maximum tail current
obtained following transfection with TRIP8b(WT) enhanced Ih
amplitude compared with HCN2 alone (HCN2 ⫹ vector, 7.2 ⫾
1.2 pA/pF; HCN2 ⫹ TRIP8b(WT), 27.3 ⫾ 3.9 pA/pF; p ⬍ 0.001;
n ⫽ 15, 13, respectively). Both phosphoablative TRIP8b constructs generated a current density that was not significantly
different from the TRIP8b(WT) condition but appears to be
in an intermediate position between the HCN2 alone and
⫹TRIP8b(WT) conditions (HCN2 ⫹ TRIP8b(S237A), 15.4 ⫾
4.3 pA/pF; HCN2 ⫹ TRIP8b(R234A), 18.3 ⫾ 4.0 pA/pF; p ⬎
0.05; n ⫽ 14, 15, respectively) (Fig. 6C). The data therefore
support the interpretation that Ser237 phosphorylation is necessary for TRIP8b-mediated hyperpolarization of channel
gating.
TRIP8b Ser237 phosphorylation and CaMKII␣ activity are
reduced in epilepsy
A prior report identified that total HCN1 protein is
unchanged in chronic epilepsy; instead, the channels are mis-
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localized and the interaction with TRIP8b is disrupted (47).
Using the KA model of TLE, we measured hippocampal HCN1
protein expression 1 h, 1 day, and 28 days post-status epilepticus (SE). Because seizures arise 2– 4 weeks post-SE in this
model, these time points correspond to the acute phase, the
latent phase before spontaneous seizures arise, and the chronic
phase exhibiting spontaneous seizures, respectively (60, 61).
We observed no change in total HCN1 protein in the hippocampus during epileptogenesis (HCN1/␤3-tubulin 1 h postSE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (1.1 ⫾ 0.1, n ⫽ 6), p ⬎ 0.05; 1 day
post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 6), KA (0.9 ⫾ 0.2, n ⫽ 5), p ⬎ 0.05;
28 days post-SE: Sal (1.00 ⫾ 0.04, n ⫽ 5), KA (1.1 ⫾ 0.1, n ⫽ 5),
p ⬎ 0.05) (Fig. 7A and Table S1).
Several kinases and phosphatases have altered activity during
epileptogenesis, including increased calcineurin and reduced
CaMKII␣ activity (43, 51, 52). Thus, we analyzed the level of
TRIP8b Ser237 phosphorylation to determine whether it is also
altered during epileptogenesis. In the KA model of TLE, seizures are generated in the hippocampus and secondarily generalize to other brain regions, including the neocortex (62, 63).
We quantified the level of Ser237 phosphorylation in the neocortex of rats in chronic epilepsy and observed no change in
Ser237 phosphorylation 28 days post-SE (pSer237/TRIP8b 28
days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (0.9 ⫾ 0.1, n ⫽ 5), p ⬎
0.05) (Fig. 7B and Table S2).
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Figure 4. Phosphorylated TRIP8b is absent from the CA3 and cerebellum but highly expressed in the CA1 region of the hippocampus. A and B,
CA3 (A) and the cerebellum region (B) stained with antibodies against TRIP8b and pSer237 (n ⫽ 3). SP, stratum pyramidale; WM, white matter; GL, granular
layer; PC, Purkinje cells; ML, molecular layer. C, protein lysate was loaded onto the gel from various mouse brain regions: 6 g total lysate from the cornu
ammonis 1 (CA1), dentate gyrus (DG), thalamus (Thal), and neocortex (Ctx) and 30 g of total lysate from the cerebellum (CB). The brain regions were
immunoblotted with the indicated antibodies. Note that different quantities of protein had to be loaded to obtain any pSer237 signal, and this led to
predictable differences in the total TRIP8b loading control. D, quantification of C, with the pSer237 level normalized to total TRIP8b; one-way analysis of
variance with Tukey’s post hoc test (CA1, 1.0; dentate gyrus, 0.2 ⫾ 0.1; thalamus, 0.3 ⫾ 0.1; neocortex, 0.5 ⫾ 0.1; cerebellum, 0.05 ⫾ 0.04) with significant
differences between the CA1 and dentate gyrus (p ⬍ 0.001), CA1 and thalamus (p ⫽ 0.001), CA1 and neocortex (p ⫽ 0.02), CA1 and cerebellum (p ⬍
0.001), and neocortex and cerebellum (p ⫽ 0.03). n ⫽ 3; *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. Scale bars ⫽ 100 m. Molecular mass markers are shown
in kilodaltons. All error bars represent mean ⫾ S.E.
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Figure 5. Phosphorylated TRIP8b at Ser237 enhances HCN1 CNBD binding. A, pictured is one subunit of an HCN channel with TRIP8b, indicating the TRIP8b
mutant constructs used: TRIP8b(N382A), TRIP8b(S237A,N382A), TRIP8b(R234A,N382A), and TRIP8b(⌬58,N382A). The N382A mutation was described previously as TPR3-N13A (21). B, HEK293T cells were transiently transfected with TRIP8b(WT), TRIP8b(N382A), TRIP8b(S237A, N382A), or TRIP8b(R234A, N382A)
constructs, and cell lysates were immunoblotted with antibodies against pSer237 and TRIP8b. The pSer237 antibody recognizes TRIP8b(WT) and TRIP8b(N382A),
but both phosphoablative constructs demonstrate a reduced signal (n ⫽ 3). C, HEK293T cells were transiently transfected with the indicated constructs. HCN1
was immunoprecipitated (IP), and HCN1 and TRIP8b were immunoblotted. D, relative immunoprecipitation of HCN1 ⫹ TRIP8b(N382A): 100,
⫹TRIP8b(S237A,N382A): 78.2 ⫾ 7.0, ⫹TRIP8b(R234A,N382A): 76.1 ⫾ 5.0, ⫹TRIP8b(⌬58,N382A): 2.1 ⫾ 1.0. One-way analysis of variance with Tukey’s post hoc
test, n ⫽ 4. Significant differences identified between ⫹TRIP8b(N382A) and ⫹TRIP8b(S237A,N382A): p ⫽ 0.02, ⫹TRIP8b(N382A) and ⫹TRIP8b(R234A,N382A):
p ⫽ 0.0098, ⫹TRIP8b(N382A) and ⫹TRIP8b(⌬58,N382A): p ⬍ 0.001, ⫹TRIP8b(S237A, N382A) and ⫹TRIP8b(⌬58,N382A), p ⬍ 0.001, ⫹TRIP8b(R234A, N382A)
and ⫹TRIP8b(⌬58,N382A): p ⬍ 0.001. E, a fluorescence polarization assay was performed with fixed concentrations of CNBD387–591 (0.625 M) and 8-f-cAMP (10
nM). Purified TRIP8b protein was incubated with CaMKII␣, with ATP (phosphorylated TRIP8b), or without ATP (nonphosphorylated TRIP8b) and titrated. F,
quantification of IC50 with phosphorylated (6.3 ⫾ 0.6 M) and nonphosphorylated (8.2 ⫾ 0.8 M) TRIP8b, n ⫽ 6, p ⫽ 0.001; matched samples were analyzed with
a paired Student’s t test. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. All error bars represent mean ⫾ S.E. Molecular mass markers are shown in kilodaltons.

We then measured the level of TRIP8b phosphorylation at
Ser237 in the hippocampus to determine whether changes take
place within the epileptogenic zone. Immediately following SE,
the level of phosphorylated TRIP8b at Ser237 was reduced in

KA-treated animals compared with saline-treated animals
(pSer237/TRIP8b, 1 h post-SE: Sal (1.00 ⫾ 0.04, n ⫽ 5), KA
(0.81 ⫾ 0.04, n ⫽ 6), p ⬍ 0.01) (Fig. 8A, i, and Table S3). To
estimate CaMKII␣ activity, we used an antibody targeting
J. Biol. Chem. (2019) 294(43) 15743–15758
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Figure 7. Hippocampal HCN1 protein expression and neocortical phosphorylated TRIP8b expression are unchanged during epileptogenesis. A, HCN1
protein was immunoblotted in hippocampal lysates harvested 1 h (i), 1 day (ii), and 28 days (iii) post-SE. HCN1 levels from Sal- and KA-treated rats were
normalized to ␤3-tubulin. Immunoblot band density was quantified using an unpaired Student’s t test; 1 Sal and 1 KA animal are shown. HCN1/␤3-tubulin; 1 h
post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (1.1 ⫾ 0.1, n ⫽ 6), p ⬎ 0.05; 1 day post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 6), KA (0.9 ⫾ 0.2, n ⫽ 5), p ⬎ 0.05; 28 days post-SE: Sal (1.00 ⫾ 0.04,
n ⫽ 5), KA (1.1 ⫾ 0.1, n ⫽ 5), p ⬎ 0.05) (Table S1). Full blots are shown in Fig. S2. B, the neocortex was harvested from Sal- or KA-treated rats 28 days post-SE.
Immunoblots were probed with antibodies against pSer237, TRIP8b, and ␤3-tubulin. Immunoblot band density was quantified using an unpaired Student’s t
test; 1 Sal and 1 KA animal are shown. pSer237/TRIP8b; 28 days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (0.9 ⫾ 0.1, n ⫽ 5), p ⬎ 0.05 (Table S2). Full blots are shown in
Fig. S2. All error bars represent mean ⫾ S.E. Molecular mass markers are shown in kilodaltons.

CaMKII␣ that is phosphorylated at Thr286, which corresponds
to the activated kinase. Although the level of pThr286-CaMKII␣
was unchanged, the loss of Ser237 phosphorylation could be a
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result of enhanced phosphatase activity that is reported following SE (pCaMKII␣/CaMKII␣ 1 h post-SE: Sal (1.0 ⫾ 0.2, n ⫽ 5),
KA (0.9 ⫾ 0.1, n ⫽ 6), p ⬎ 0.05) (Fig. 8B, i, and Table S3) (52).
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Figure 6. TRIP8b with a phosphoablative mutation prevents hyperpolarization of HCN2 gating. A, representative current traces from HEK293 cells stably
expressing HCN2 and transiently transfected with GFP and TRIP8b(WT), TRIP8b(S237A), TRIP8b(R234A), or control vector. Whole-cell recordings were performed with cells held at ⫺40 mV in voltage clamp and stepped from ⫺40 to ⫺120 mV. B, quantification of V50; HCN2 ⫹ vector: ⫺90.1 ⫾ 1.6 mV (n ⫽ 15), HCN2
⫹TRIP8b(WT): ⫺95.3 ⫾ 1.6 mV (n ⫽ 13), HCN2 ⫹ TRIP8b(S237A): ⫺88.3 ⫾ 2.2 mV (n ⫽ 14), HCN2 ⫹ TRIP8b(R234A): ⫺83.9 ⫾ 2.3 mV (n ⫽ 15). Independent
Student’s t tests were performed to compare TRIP8b(WT) to each condition; ⫹TRIP8b(WT) and ⫹ vector: p ⫽ 0.03, ⫹TRIP8b(WT) and ⫹TRIP8b(S237A): p ⫽ 0.02,
⫹TRIP8b(WT) and ⫹TRIP8b(R234A): p ⬍ 0.001. C, maximum tail current was divided by the cell capacitance to obtain Ih current amplitude for each condition.
HCN2 ⫹ vector: 7.2 ⫾ 1.2 pA/pF (n ⫽ 15), HCN2 ⫹ TRIP8b(WT): 27.3 ⫾ 3.9 pA/pF (n ⫽ 13), HCN2 ⫹ TRIP8b(S237A): 15.4 ⫾ 4.3 pA/pF (n ⫽ 14), HCN2 ⫹
TRIP8b(R234A): 18.3 ⫾ 4.0 pA/pF (n ⫽ 15). Student’s t tests were similarly performed to compare TRIP8b(WT) with each condition; ⫹TRIP8b(WT) and ⫹vector:
p ⬍ 0.001, ⫹TRIP8b(WT) and ⫹TRIP8b(S237A): p ⫽ 0.054, ⫹TRIP8b(WT) and ⫹TRIP8b(R234A): p ⫽ 0.1. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. All error bars
represent mean ⫾ S.E.
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Both 1 day and 28 days post-SE, TRIP8b phosphorylation at
Ser237 and pThr286-CaMKII␣ were reduced in the hippocampus of KA-treated animals (pSer237/TRIP8b 1 day post-SE: Sal
(1.0 ⫾ 0.1, n ⫽ 6), KA (0.7 ⫾ 0.1, n ⫽ 5), p ⬍ 0.01; pSer237/
TRIP8b 28 days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 10), KA (0.7 ⫾ 0.1,
n ⫽ 11), p ⬍ 0.01; pCaMKII␣/CaMKII␣ 1 day post-SE: Sal
(1.0 ⫾ 0.1, n ⫽ 6), KA (0.5 ⫾ 0.2, n ⫽ 5), p ⬍ 0.05); pCaMKII␣/
CaMKII␣ 28 days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (0.63 ⫾
0.04, n ⫽ 5), p ⬍ 0.01) (Fig. 8, A and B, and Table S3). These data
establish that phosphorylated TRIP8b at Ser237 is reduced
throughout the time course of epileptogenesis and that the
change is localized to the epileptogenic zone.

Discussion
In this study, we have shown that TRIP8b phosphorylation regulates HCN channel binding and function. TRIP8b binding results
in a unique CNBD conformation, one that both hyperpolarizes
gating and reduces cAMP affinity for the CNBD (20, 21, 26, 28).
The identity of the specific amino acid residues responsible for the
TRIP8b interaction with the CNBD has been the subject of several
recent in vitro studies, one of which identified the nano domain as
necessary and sufficient for TRIP8b binding to the HCN CNBD
(54). Residue Ser237 is located within the nano domain, where it is
predicted to influence the effect of TRIP8b on channel gating and
trafficking (21, 22, 26, 29, 54).
J. Biol. Chem. (2019) 294(43) 15743–15758
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Figure 8. Reduction in TRIP8b phosphorylation and CaMKII␣ activity in the KA model of TLE. A and B, hippocampi were harvested from Sal- or KA-treated
rats 1 h (i), 1 day (ii), or 28 days (iii) post-SE. Immunoblots were probed with antibodies against pSer237, TRIP8b, and ␤3-tubulin (A) or pCaMKII␣ and CaMKII␣ (B).
Immunoblot band density was quantified using unpaired Student’s t test; 3 Sal and 3 KA animals are shown. A, pSer237/TRIP8b: 1 h post-SE: Sal (1.00 ⫾ 0.04, n ⫽
5), KA (0.81 ⫾ 0.04, n ⫽ 6), p ⬍ 0.01; 1 day post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 6), KA (0.7 ⫾ 0.1, n ⫽ 5), p ⬍ 0.01; 28 days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 10), KA (0.7 ⫾ 0.1, n ⫽
11), p ⬍ 0.01. B, pCaMKII␣/CaMKII␣, 1 h post-SE: Sal (1.0 ⫾ 0.2, n ⫽ 5), KA (0.9 ⫾ 0.1, n ⫽ 6), p ⬎ 0.05; 1 day post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 6), KA (0.5 ⫾ 0.2, n ⫽ 5),
p ⬍ 0.05); 28 days post-SE: Sal (1.0 ⫾ 0.1, n ⫽ 5), KA (0.63 ⫾ 0.04, n ⫽ 5), p ⬍ 0.01) (Table S3). *, p ⬍ 0.05; **, p ⬍ 0.01. Full blots are shown in Fig. S3. All error bars
represent mean ⫾ S.E. Molecular mass markers are shown in kilodaltons.
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ization of channel gating. Phosphoablative TRIP8b constructs
prevent this shift in activation voltage, which is consistent with
our in vitro binding experiments that indicate that these constructs have a lowered affinity for the CNBD.
Implications for TLE
We observed that Ser237 phosphorylation was altered in a rat
model of TLE, raising the possibility that these changes could
be involved in producing HCN channel dysfunction. Both pilocarpine and KA models of TLE demonstrate reduced HCN
channel function and dendritic expression in chronic epilepsy
(42, 44, 46, 47). We noted that 1 h, 1 day, and 28 days post-SE,
TRIP8b phosphorylation is significantly reduced. Given that
Ser237 is dephosphorylated within an hour of SE, it is possible
that this abnormality is essential to epileptogenesis. Although
the loss of phosphorylation 1 h post-SE cannot be explained by
a reduction in CaMKII␣ activity, it may be due to increased
calcineurin activity, which has been observed following SE (52).
However, loss of TRIP8b phosphorylation during the latent and
chronic phases correlates with reduced CaMKII␣ activity and
may be maintained by dysregulation of this kinase pathway.
The reduction of TRIP8b phosphorylation at early time points
may initiate dissociation of the TRIP8b–HCN complex that
is observed in chronic epilepsy, leading to reduced dendritic
channel trafficking and Ih (47). We identified reduced phosphorylation in the hippocampus, but interestingly, phosphorylation levels remained stable in the neocortex in chronic epilepsy. The data suggest that the reduction of Ser237 phosphorylation is specific to the epileptogenic zone and may play a role
in development of epilepsy in the hippocampus.
In summary, this report identifies a posttranslational
modification of TRIP8b at residue Ser237 as a regulator of
HCN channel function under physiological conditions and
TLE. Restoring TRIP8b phosphorylation at this site may
strengthen HCN1 channel binding and dendritic trafficking
to enhance Ih in TLE.

Experimental procedures
Immunoprecipitation for mass spectrometry
All animal use procedures were in strict accordance with the
Guide for the Care and Use of Laboratory Animals described by
the National Institutes of Health and approved by the University of California Davis Institutional Animal Care and Use
Committee. Adult female Sprague-Dawley rats (Charles River
Laboratories, Wilmington, MA), were injected with either
saline or kainic acid to induce acute seizures using a single i.v.
dose of 10 mg/kg. For KA-treated rats, behaviors were scored
according to the Racine scale, and rats were euthanized immediately after reaching level 5 seizures (66). Hippocampi from
both treatment groups were harvested and homogenized on ice
in 2 ml of ice-cold homogenization buffer (20 mM Tris-HCl (pH
8.0), 320 mM sucrose and protease inhibitors). The homogenate
was then diluted to 0.5 mg/ml and solubilized in ice-cold buffer
containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM
EDTA, 5 mM NaF, 1% Triton-X-100, 1 mM NaOV4, and protease inhibitors. Insoluble material was pelleted at 16,000 ⫻ g for
10 min at 4 °C and discarded. The resulting lysate was then
subjected to immunoprecipitation overnight at 4 °C with a rab-
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We conclude that TRIP8b can be phosphorylated at residue
Ser237 by CaMKII␣ and PKA and that the presence of the phosphate group increases the affinity of TRIP8b for the HCN
CNBD (Figs. 2D and 5). Our in vitro experiments using purified
proteins produced results that were consistent with those seen
in other expression systems, suggesting that additional proteins
are unlikely to mediate the increased affinity. The negatively
charged TRIP8b nano domain is thought to be drawn to the
positively charged residues of the HCN CNBD. Immediately
C-terminal to TRIP8b Ser237 is a series of negatively charged
residues, EEEFE (239 –243). Reversing the charge of this
stretch has been shown previously to reduce TRIP8b binding
to the HCN1 CNBD (64). Additionally, reversing the charge
of two positively charged lysine residues (665 and 666) in the
HCN2 CNBD reduces the binding affinity between the
CNBD and TRIP8b (27). Thus, we reason that addition of a
negatively charged phosphate group to Ser237 contributes to
stabilization of TRIP8b binding to the CNBD. In addition to
the effect of electrostatic interactions, dephosphorylation at
Ser237 could interfere with the structural changes that naturally occur within the TRIP8b nano domain and the CNBD to
reduce binding (54).
This work demonstrates that phosphorylation of Ser237 contributes to the high-affinity TRIP8b-HCN binding that is essential for dendritic trafficking and surface expression of HCN
channels in the distal dendrites of CA1 pyramidal neurons. Distal dendritic enrichment of HCN1 in the hippocampus depends
on an intact CNBD interaction (involving a stretch of TRIP8b
that includes Ser237) as well as CaMKII␣ activity (22, 48). The
homeostatic increase in Ih observed following long-term potentiation is also dependent on CaMKII␣ activity, which raises the
possibility that Ser237 phosphorylation may be enhanced and
contribute to Ih up-regulation in these instances (65). Because
both TRIP8b-HCN binding sites are necessary for successful
dendritic trafficking, there may be either a minimum strength
of interaction required or some essential conformation of the
proteins that is modulated by phosphorylation. The strength of
the two TRIP8b-binding interactions involves allosteric modulation by TRIP8b, whereby binding to HCN at either site
increases the affinity of the other (58). Thus, the loss of Ser237
phosphorylation we observed in epilepsy may not only affect
the CNBD interaction but propagate downstream to weaken
the C-terminal tail interaction as well. The role of phosphorylated Ser237 in dendritic channel enrichment is supported by
data indicating that TRIP8b is not phosphorylated in regions
containing somatic or presynaptic HCN channels but specifically phosphorylated in cells exhibiting dendritic channel
enrichment. One possibility not addressed here is that Ser237
phosphorylation could be a consequence rather than a cause of
dendritic channel targeting. Additional experiments will be
necessary to distinguish whether Ser237 phosphorylation regulates both dendritic channel targeting and surface trafficking or
only one aspect of TRIP8b function.
TRIP8b binding to the HCN channel CNBD generates
hyperpolarization of channel activation, but the net result is
enhanced channel trafficking and increased current density in
CA1 (21, 22). Our electrophysiology data demonstrate that
TRIP8b phosphorylation at Ser237 is necessary for hyperpolar-
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bit TRIP8b polyclonal antibody (generated against a C-terminal
His-tagged fragment corresponding to aa 396 – 462 of TRIP8b).
Immunopurified products were recovered by incubation with
DynaBeads for 1 h at 4 °C, followed by three washes using icecold solubilization buffer and 1 wash with ice-cold detergentfree solubilization buffer. The beads were then removed to a
fresh microfuge tube for nine more additional washes with icecold detergent free buffer. The final immunoprecipitation
products were then eluted by boiling in 50 l reducing SDS
sample buffer.

Animals

Sample preparation for mass spectrometry

Phosphorylated TRIP8b antibody was generated by YenZym Antibodies, LLC (South San Francisco, CA). The
immunogen used was a 15-amino acid peptide spanning residues 234 –247 (RNHpSLEEEFERAKA) containing the phosphorylated serine residue. Rabbits were immunized with the
synthesized peptide conjugated to keyhole limpet hemocyanin, and the elicited antiserum was subjected to peptide
affinity absorption and purification to isolate the phosphospecific antibody components. The antibody is referred to as
pSer237. All TRIP8b residues described in this manuscript
use the Rattus norvegicus isoform 1a-4 (UniProt Q925N3) as
a reference sequence.

LC-MS/MS analysis
LC-MS/MS analysis was performed at the UC Davis Proteomics Core Facility. LC separation was performed on a Nano
Acquity UHPLC (Waters Corp.) with a Proxeon nanospray
source. The digested peptides were reconstituted in 2% acetonitrile/0.1% TFA, and roughly 3 g of each sample was loaded
onto a 100 m ⫻ 25 mm Magic C18 100 Å 5U reverse-phase
trap column and desalted online before being separated on a 75
m ⫻ 150 mm Magic C18 200 Å 3U reverse-phase column.
Peptides were eluted using a gradient of 0.1% formic acid (A)
and 100% acetonitrile (B) with a flow rate of 300 nL/min. A
120-min gradient was run with 5% to 35% B over 100 min, 35%
to 80% B over 8 min, 80% B for 1 min, and 80% to 5% B over 1
min and finally held at 5% B for 10 min. Each of the gradients
was followed by a 1-h column wash.
Mass spectra were collected on an Orbitrap Q Exactive Plus
mass spectrometer (Thermo Fisher Scientific) in a data-dependent mode with one MS precursor scan followed by 15 MS/MS
scans. A dynamic exclusion of 15 s was used. MS spectra were
acquired with a resolution of 70,000 and a target of 1 ⫻ 106 ions
or a maximum injection time of 30 ms. MS/MS spectra were
acquired with a resolution of 17,500 and a target of 5 ⫻ 104 ions
or a maximum injection time of 50 ms. Peptide fragmentation
was performed using higher-energy collision dissociation with
a normalized collision energy value of 27. Unassigned charge
states as well as ⫹1 and ions ⬎⫹5 were excluded from MS/MS
fragmentation.

Phospho-specific antibody pSer237

Immunoblotting
Protein extracts were obtained from mouse or rat brain
regions as indicated, homogenized, and sonicated briefly on ice
in 20 mM HEPES (pH 7.4), 100 mM NaCl, 5 mM EDTA, and 5 mM
EGTA with Halt protease and phosphatase inhibitor mixture
(ThermoFisher) and 1% Triton X-100 and then centrifuged at
21,000 ⫻ g for 10 min at 4 °C (Figs. 2C; 3B; 4C; 7, A, iii, and B;
and 8, A, iii, and B, iii) or 20 mM HEPES (pH 7.4), 320 mM
sucrose, 5 mM EDTA, and 5 mM EGTA with Halt protease and
phosphatase inhibitor mixture (ThermoFisher) and then centrifuged at 750 ⫻ g for 10 min at 4 °C (Figs. 7A, i and ii, and 8, A,
i and ii, and B, i and ii). Protein concentration was determined
using a Bradford protein assay (ThermoFisher), and samples
were boiled in Laemmli sample buffer (Bio-Rad) containing
␤-mercaptoethanol (BME) at 95 °C for 5 min. Immunoblotting
was performed as described previously (47). The proteins were
resolved by SDS-PAGE and transferred to Immobilon-P PVDF
membranes (Millipore, Billerica, MA) and incubated with
blocking solution for 1 h at room temperature (5% milk or 5%
BSA and 0.1% Tween 20 in TBS (TBS-T)). Primary antibodies
were diluted in blocking solution: mouse ␣-TRIP8b (1:1500,
NeuroMab clone N212/17; RRID: AB_10698035), custom rabbit ␣-TRIP8b C terminus (1:1000), mouse anti-␣-tubulin
(1:1000, Millipore, 05-829; RRID: AB_310035), custom rabbit
anti-pSer237 (1:1000, YenZym), mouse anti-total CaMKII␣
(1:1500, ThermoFisher, MA1– 048, RRID: AB_325403), rabbit
anti-pThr286 CaMKII␣/␤ (1:1500, ThermoFisher, PA1-4614,
RRID: AB_2259386), custom rabbit anti-HCN1 (1:1000), and
mouse anti-␤3-tubulin (1:10,000, Sigma-Aldrich, T2200, RRID:
AB_262133). Primary antibodies were incubated at room temperature for 1 h or overnight at 4 °C. Secondary antibodies were
prepared in blocking solution and incubated at room temperature for 1 h and imaged either using the near-IR detection system (Li-Cor Biosciences, IRDye 800CW, 680RD) or Pierce ECL
J. Biol. Chem. (2019) 294(43) 15743–15758
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Immunoprecipitation products were resolved on a 7.5%
SDS-PAGE gel and visualized by colloidal blue Coomassie
stain. Bands corresponding to ⬇66 kDa were excised for in-gel
digestion for both saline- and KA-treated tissues as reported
previously (66). Briefly, samples were destained with 50% acetonitrile and washed extensively with distilled water. Proteins
were then reduced in 10 mM DTT at 56 °C for 1 h and alkylated
in 5 mM iodoacetamide at room temperature for 30 min. Gel
pieces were then washed and dehydrated prior to rehydration
with trypsin solution (Promega, Madison, WI) at 12.5 ng/ml in
50 mM ammonium bicarbonate and incubated overnight at
37 °C. Digested peptide mixtures were extracted three times
with 10% formic acid for 15 min on ice and 100% acetonitrile for
5 min at room temperature. Extracted peptides were desalted
and stored on StageTip C18 at 4 °C (or room temperature) until
LC-MS/MS.

All additional animal experiments were performed according to protocols approved by the Institutional Animal Care and
Use Committees of Northwestern University and Vanderbilt
University. Adult male and female C57BL/6 mice (2–12
months) were obtained from The Jackson Laboratory (Ellsworth, ME). Adult male Sprague-Dawley rats (2–3 months)
were obtained from Charles River Laboratories (Wilmington,
MA).
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substrate (ThermoFisher). Band intensities were quantified
using Li-Cor ImageStudio software.
Phosphatase treatment
Hippocampal lysates from WT mice were incubated with 1.5
units/50-l reaction of CIP (New England Biolabs) for 2 h at
37 °C before Western blotting as above.
HEK293T cell transfection and preparation

Recombinant protein purification
TRIP8b(219 – 602) and HCN1 CNBD(387–591) were cloned and
generated as described previously (58). Protein constructs were
purified as described elsewhere using nickel-nitrilotriacetic
acid chromatography (Qiagen, Hilden, Germany) (67). Protein
purity was analyzed by Coomassie staining, and protein concentration was detected by Bradford assay (ThermoFisher).
In vitro protein kinase assay
Purified TRIP8b(219 – 602) (residue numbering based on
mouse TRIP8b isoform 1a-4) was incubated with CaMKII␣
enzyme (New England Biolabs, P6060), CaCl2, calmodulin, and
CaMKII␣ protein kinase buffer (according to the manufacturer’s instructions) with or without 200 M ATP for 30 min at
30 °C. Purified TRIP8b(219 – 602) protein was also incubated with
PKA (New England Biolabs, P6000) and protein kinase buffer
with or without 200 M ATP for 30 min at 30 °C. The reactions
were terminated in Laemmli sample buffer (Bio-Rad) containing BME and boiled at 95 °C for 5 min. The protein was resolved
by SDS-PAGE and immunoblotted using the indicated
antibodies.
Immunohistochemistry
Immunohistochemistry was performed as described previously (68). Mice were deeply anesthetized with isoflurane and
transcardially perfused with ice-cold PBS followed by 4% paraformaldehyde. Brains were removed and post-fixed for 48 h at
4 °C. Coronal sections (30 m) were made using a vibratome
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Coimmunoprecipitation
HEK293T cells were maintained and transfected as described above. 48 h post-transfection, cells were washed with
PBS and lysed in 600 l of TEEN-TX buffer (50 mM Tris, 1 mM
EDTA, 1 mM EGTA, 150 mM NaCl, and 0.1% Triton X-100)
supplemented with Halt protease and phosphatase inhibitor
mixture (ThermoFisher). For coimmunoprecipitation from
hippocampal lysate, the hippocampus was dissected in ice-cold
PBS and lysed in 20 mM HEPES (pH 7.4), 100 mM NaCl, 5 mM
EDTA, and 5 mM EGTA with Halt protease and phosphatase
inhibitor mixture (ThermoFisher) and 1% Triton X-100.
Lysates were sonicated briefly on ice and centrifuged at
21,000 ⫻ g for 10 min. A 50-l aliquot of the supernatant
(labeled “input”) was added to 12.5 l of Laemmli sample buffer
(Bio-Rad) containing BME and boiled at 95 °C for 5 min. Custom guinea pig anti-HCN1 antibody (4 –5 l for HEK293T
samples) or mouse anti-TRIP8b exon 4 (5 l for hippocampal
samples, NeuroMab, clone N212/3, RRID: AB_10671951) was
added to 450 l of the remaining lysate and rotated at 4 °C
overnight. The next day, 40 l of protein A/G agarose bead
slurry (ThermoFisher) was washed three times in TEEN-TX,
added to the antibody-coupled sample, and nutated for 2 h at
4 °C. The beads were then washed in TEEN-TX buffer five
times, 5 min each time, nutating at 4 °C, and then eluted by
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HEK293T cells were maintained in DMEM with 10% FBS
and 1% penicillin streptomycin. Cells were plated into 6-well
tissue culture plates and transiently transfected 24 h later with
an empty vector or TRIP8b construct using TransIT-LT1
(MirusBio) according to the manufacturer’s instructions at a
ratio of 1:3, HCN:TRIP8b. The TRIP8b(S237A) mutation was
generated by two-stage PCR amplification using 5⬘-ggaaccatgccttggaagaggagtttg-3⬘ and 5⬘-cttccaaggcatggttcctggagag-3⬘ and
reinserted into pxEGFP-C1-TRIP8b at EcoRI/BamHI sites. The
TRIP8b(N382) mutation was generated as described previously
(21), and the TRIP8b(R234A) mutation was generated using the
QuikChange XL II kit with 5⬘-gaagtgccctgctctccgcgaaccattccttggaag-3⬘ and 5⬘-cttccaaggaatggttcgcggagagcagggcacttc-3⬘
(Agilent). 48 h post-transfection, cells were lysed with
TEEN-TX (50 mM Tris, 1 mM EDTA, 1 mM EGTA, 150 mM
NaCl, and 0.1% Triton X-100) containing Halt protease and
phosphatase inhibitor mixture (ThermoFisher). Cell lysates
were sonicated briefly on ice and centrifuged at 21,000 ⫻ g for
10 min. The supernatant was then used for Western blotting as
above.

(Leica), and antigen retrieval was performed with 10 mM
sodium citrate (pH 9.0) for 10 min at 80 °C. Slices were allowed
to cool, washed with PBS, and immersed in blocking solution
(5% normal goat serum and 0.03% Triton X-100 in PBS) for 1 h
at room temperature with gentle agitation. The following primary antibodies were diluted in blocking solution and applied
overnight at 4 °C: custom guinea pig anti-HCN1 (1:3000),
mouse anti-TRIP8b (1:1000, NeuroMab, clone N212/17, RRID:
AB_10698035), rabbit anti-pSer237 (1:1000, YenZym), custom
guinea pig anti-HCN2 (1:1000), mouse anti-Olig2 (1:1000, Millipore, MABN50, RRID: AB_10807410), and mouse antiTRIP8b exon 4 (1:1000, NeuroMab, clone N212/3, RRID:
AB_10671951). Sections were then washed three times for 5
min each and incubated with fluorescently labeled secondary
antibodies (Invitrogen) in blocking solution for 1 h at room
temperature. Sections were then washed an additional three
times with 4⬘,6-diamidino-2-phenylindole included in the final
wash. The tissue was mounted on glass slides using PermaFluor
(ThermoFisher). Images were acquired on an Olympus Fv10i
confocal microscope (FluoView Software) using a ⫻10 or ⫻60
oil immersion objective with or without ⫻2 digital zoom. Imaging work was also performed at the Northwestern University
Center for Advanced Microscopy, generously supported by
NCI, National Institutes of Health CCSG P30 CA060553,
awarded to the Robert H. Lurie Comprehensive Cancer Center, on a Nikon A1R confocal microscope using a ⫻20 objective. Images were also acquired in part through use of the
Vanderbilt Cell Imaging Shared Resource (supported by
National Institutes of Health Grants CA68485, DK20593,
DK58404, DK59637, and EY08126). WT and KO tissues used
for comparison were prepared simultaneously, and images
were acquired and presented with identical settings using
Fiji software.
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boiling in 40 l of Laemmli sample buffer (Bio-Rad) containing
BME at 95 °C for 5 min. Samples were resolved by SDS-PAGE
(HEK293T cells: 8 l of input and eluate; hippocampi: 10 l of
input, supernatant, and eluate). Densitometry of band intensity
was performed using Li-Cor ImageStudio software, and the
level of TRIP8b elution was divided by HCN1 elution for each
condition.
Fluorescence polarization

Electrophysiology
Electrophysiology was performed as described in Ref. 20 with
modifications. HEK293 cells stably expressing HCN2 were generated by transfecting cells with mouse HCN2 in the pcDNA3
plasmid using TransIT-LT1 (MirusBio) transfection reagent
according to the manufacturer’s protocol. 24 h post-transfection, G418 (0.5 mg/ml final concentration, Sigma-Aldrich) was
added to the culture medium. Cells were maintained in G418
solution for 6 weeks for selection of cells stably expressing the
pcDNA-HCN2 construct, and then aliquots were frozen in culture medium with 5% DMSO (Sigma) and stored in liquid
nitrogen.
Cells were plated on autoclaved 12 mm-diameter Germanglass coverslips coated with poly-L-lysine (0.1 mg/ml, Sigma)
and washed with Hank’s balanced salt medium (without calcium or magnesium). Cells were transiently transfected 18 –24
h later with EGFP plus a control vector, TRIP8b(WT),
TRIP8b(S237A), or TRIP8b(R234A), using Lipofectamine 2000
(according to the manufacturer’s instructions with modifications). Lipofectamine exposure was limited to 60 min, followed
by a rinse and replacement using preconditioned culture
medium. Whole-cell recordings were performed 24 – 48 h after
transfection with pipettes made from borosilicate glass using a
vertical puller (Narishige) with a final resistance of ⬃2.5–3.5

Kainic acid injections
Rats were allowed to acclimate in the on-site animal facility
for at least 1 week prior to the experiment with food and water
ad libitum. SE was induced by repeated low-dose intraperitoneal injections of KA dissolved in sterile saline (5 mg/kg; Tocris,
Ellisville, MO) every 30 – 45 min. To reduce mortality, rats
received full doses (5 mg/kg) or half-doses (2.5 mg/kg) of KA
according to seizure progression. Control rats (no KA) were
given equivalent injections of sterile saline. Seizures were
scored using a modified Racine scale (69): stage 1, behavioral
arrest with facial automatisms; stage 2, head nodding; stage 3,
forelimb clonus; stage 4, forelimb clonus with rearing; stage 5,
rearing and falling. Status epilepticus was terminated as
described previously (47) using diazepam (10 mg/kg i.p. injection or up to 15 mg/kg as needed to terminate SE) (70). To
prevent dehydration and minimize discomfort, animals were
given subcutaneous injections of warmed lactated Ringer’s
solution as needed and monitored closely in the days following
SE induction. For the 1 h and 1 day post-SE experiments, 11 rats
were injected with saline, and 14 rats were injected with KA (3
of 14 died in SE). These rats were divided into five control rats
and six KA rats for the 1 h post-SE experiment and six control
rats and five KA rats for the 1 day post-SE experiment. For the
28 days post-SE experiment, five rats were injected with saline,
and eight rats were injected with KA (one rat died in SE, and two
rats died prior to the 28-day time point), leaving five KA rats for
analysis.
Statistics
Data were analyzed using Student’s t test for two groups or
one-way analysis of variance with Tukey’s post hoc test for pairJ. Biol. Chem. (2019) 294(43) 15743–15758
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CNBD and 8-f-cAMP oligonucleotides were synthesized by
Integrated DNA Technologies (Coralville, IA). The HCN1
CNBD fragment used spans residues 387–591 of the mouse
HCN1 isoform and contains a maltose-binding protein tag to
enhance protein purification yield. Fluorescence polarization
experiments were performed as described previously with
modifications (58). Prior to these experiments, TRIP8b protein
was incubated with CaMKII enzyme (New England Biolab),
CaCl2, CaM, and protein kinase buffer according to manufacturer’s instructions with or without 200 mM ATP. A series of
2-fold TRIP8b dilutions was then titrated into 0.625 M HCN1
CNBD peptide and 10 nM 8-f-cAMP with sterile filtered PBS
and 1 mM DTT. Samples were loaded in triplicate in black 384well microtiter plates (Corning, Corning, NY), and polarization
measurements were obtained using a Tecan microplate reader
(Tecan, Zurich, Switzerland) at the Structural Biology facility at
Northwestern University. We acknowledge staff and instrumentation support from the Structural Biology Facility at
Northwestern University, the Robert H. Lurie Comprehensive
Cancer Center of Northwestern University, and NCI, National
Institutes of Health CCSG P30 CA060553. Curve fitting and
data analysis were performed using Igor Pro (WaveMetrics).
Curves were fit by the Hill equation based on a previous report
(58).

megaohms. Cells were held at ⫺40 mV in voltage clamp and
progressively stepped (⫺10 mV) from ⫺40 to ⫺120 mV. Extracellular solution consisted of 145 mM NaCl, 10 mM KCl, 10 mM
glucose, 10 mM HEPES, 2 mM CaCl2, and 1 mM MgCl2 buffered
to pH 7.4 and an osmolarity of 312–315 mOsmol. The intracellular pipette solution contained 135 mM potassium gluconate,
10 mM MgCl2, 0.1 mM CaCl2, 1 mM EGTA, 10 mM HEPES, and
2 mM Mg-ATP buffered to pH 7.3 and an osmolarity of 295–305
mOsmol. Maximal tail current amplitude populations measured from each cell were fit to the Boltzmann equation as
described in Ref. 20. Maximal Ih current density was calculated
by dividing the maximal tail current by the cell capacitance, as
described in Ref. 24. Currents were recorded via WinWCP software (University of Strathclyde), a MultiClamp 700A amplifier
(Molecular Devices), and a National Instruments USB6221
interface card. The sampling rate was 10 kHz. Voltage clamping
and series resistance were monitored throughout each experiment, and cells were discarded if the series resistance rose during the experiment. Two-tailed t tests were used to compare
each group with the TRIP8b(WT)-transfected condition to test
hypotheses generated by a pilot experiment. Expression of
TRIP8b(WT) and its aforementioned mutants during the electrophysiology experiments described above were confirmed by
subjecting cell samples of the exact same transfected conditions
described above to Western blotting using an ␣-TRIP8b antibody (data not shown).
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wise comparisons among three or more groups. Electrophysiology data were analyzed using Student’s t test for comparison
between TRIP8b(WT) and each additional condition in a pairwise manner as indicated. Data are represented as mean ⫾ S.E.
(*, p ⬍ 0.05, **, p ⬍ 0.01, ***, p ⬍ 0.001).
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